New study raises new questions about Merck cholesterol drug

Merck's ($MRK) experimental cholesterol drug anacetrapib, part of a huge study that won't yield final data till 2017, is already an expensive, risky bet. But it may be even riskier than previously considered: A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.